中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2010年
4期
293-295
,共3页
马健%李亚利%董梅%王玉甫%齐宝庆
馬健%李亞利%董梅%王玉甫%齊寶慶
마건%리아리%동매%왕옥보%제보경
糖尿病,2型%骨折%6-酮-前列腺素F_(1α)%血液凝固
糖尿病,2型%骨摺%6-酮-前列腺素F_(1α)%血液凝固
당뇨병,2형%골절%6-동-전렬선소F_(1α)%혈액응고
Diabetes mellitus,type 2%Fractures bone%Thrombosis molecular 6-ketoprostaglandin F1 alpha%Blood coagulation markers
目的 探讨骨折对老年2型糖尿病患者凝血活性的影响及与发生血栓性疾病的关系.方法 测定80例老年2型糖尿病合并下肢骨折患者、80例老年2型糖尿病患者、60例年龄、体质指数相匹配的健康对照者的血浆6-酮-前列腺素F1α(6-keto-PGF1α)、血小板α颗粒膜蛋白-140(GMP-140)、血栓素B2(TXB2)、纤维蛋白原(FIB)、D-二聚体(D-D)水平,组间进行比较. 结果糖尿病合并骨折组的6-keto-PGF1α测定值为(49.86±6.01)ng/L,糖尿病组为(58.92±6.44)ng/L,健康对照组为(75.34±8.21)ng/L,前两组较健康对照组的6-keto-PGF1α测定值均下降,且糖尿病合并骨折组的6-keto-PGF1α值较糖尿病组下降(F=238.776,P=0.000);糖尿病合并骨折组GMP-140、TXB2、FIB和D-D测定值分别为(21.86±2.57)μg/L、(139.46±16.80)ng/L、(5.19±0.89)g/L和(1.13±0.27)mg/L,糖尿病组的相应测定值分别为(17.92±2.50)μg/L、(126.07±7.64)ng/L、(4.52±0.80)g/L和(0.73±0.27)mg/L,健康对照组的相应测定值分别为(13.85±1.20)μg/L、(76.94±10.60)ng/L、(3.26±0.84)g/L和(0.29±0.15)mg/L,前两组的各测定值较健康对照组均升高,且糖尿病合并骨折组较糖尿病组升高(F=191.407、463.307、90.705、202.685,均P=0.000).结论 骨折可增强老年2型糖尿病患者的凝血活性,加剧其高凝状态,容易发生血栓性疾病,应早期干预治疗.
目的 探討骨摺對老年2型糖尿病患者凝血活性的影響及與髮生血栓性疾病的關繫.方法 測定80例老年2型糖尿病閤併下肢骨摺患者、80例老年2型糖尿病患者、60例年齡、體質指數相匹配的健康對照者的血漿6-酮-前列腺素F1α(6-keto-PGF1α)、血小闆α顆粒膜蛋白-140(GMP-140)、血栓素B2(TXB2)、纖維蛋白原(FIB)、D-二聚體(D-D)水平,組間進行比較. 結果糖尿病閤併骨摺組的6-keto-PGF1α測定值為(49.86±6.01)ng/L,糖尿病組為(58.92±6.44)ng/L,健康對照組為(75.34±8.21)ng/L,前兩組較健康對照組的6-keto-PGF1α測定值均下降,且糖尿病閤併骨摺組的6-keto-PGF1α值較糖尿病組下降(F=238.776,P=0.000);糖尿病閤併骨摺組GMP-140、TXB2、FIB和D-D測定值分彆為(21.86±2.57)μg/L、(139.46±16.80)ng/L、(5.19±0.89)g/L和(1.13±0.27)mg/L,糖尿病組的相應測定值分彆為(17.92±2.50)μg/L、(126.07±7.64)ng/L、(4.52±0.80)g/L和(0.73±0.27)mg/L,健康對照組的相應測定值分彆為(13.85±1.20)μg/L、(76.94±10.60)ng/L、(3.26±0.84)g/L和(0.29±0.15)mg/L,前兩組的各測定值較健康對照組均升高,且糖尿病閤併骨摺組較糖尿病組升高(F=191.407、463.307、90.705、202.685,均P=0.000).結論 骨摺可增彊老年2型糖尿病患者的凝血活性,加劇其高凝狀態,容易髮生血栓性疾病,應早期榦預治療.
목적 탐토골절대노년2형당뇨병환자응혈활성적영향급여발생혈전성질병적관계.방법 측정80례노년2형당뇨병합병하지골절환자、80례노년2형당뇨병환자、60례년령、체질지수상필배적건강대조자적혈장6-동-전렬선소F1α(6-keto-PGF1α)、혈소판α과립막단백-140(GMP-140)、혈전소B2(TXB2)、섬유단백원(FIB)、D-이취체(D-D)수평,조간진행비교. 결과당뇨병합병골절조적6-keto-PGF1α측정치위(49.86±6.01)ng/L,당뇨병조위(58.92±6.44)ng/L,건강대조조위(75.34±8.21)ng/L,전량조교건강대조조적6-keto-PGF1α측정치균하강,차당뇨병합병골절조적6-keto-PGF1α치교당뇨병조하강(F=238.776,P=0.000);당뇨병합병골절조GMP-140、TXB2、FIB화D-D측정치분별위(21.86±2.57)μg/L、(139.46±16.80)ng/L、(5.19±0.89)g/L화(1.13±0.27)mg/L,당뇨병조적상응측정치분별위(17.92±2.50)μg/L、(126.07±7.64)ng/L、(4.52±0.80)g/L화(0.73±0.27)mg/L,건강대조조적상응측정치분별위(13.85±1.20)μg/L、(76.94±10.60)ng/L、(3.26±0.84)g/L화(0.29±0.15)mg/L,전량조적각측정치교건강대조조균승고,차당뇨병합병골절조교당뇨병조승고(F=191.407、463.307、90.705、202.685,균P=0.000).결론 골절가증강노년2형당뇨병환자적응혈활성,가극기고응상태,용역발생혈전성질병,응조기간예치료.
Objective To explore the effect of lower extremity fracture (LEF) on the coagulation activity and the relationship between LEF and thrombotic diseases in the elderly type 2 diabetic patients. Methods This study included three groups: 80 elderly patients with type 2 diabetes mellitus plus LEF (DM plus fracture), 80 elderly patients with type 2 diabetes mellitus without fracture (DM) and 60 healthy (Cont.) persons with same age and body weight index. The 6-keto-PGF1α, GMP-140, TXB2, FIB and D-D levels of the 3 groups were tested and compared. Results The levels of 6-keto-PGF1α were significantly lower in groups of DM plus fracture and DM [(49.86±6.01) ng/L and (58.92±6.44) ng/L] than in control group [(75.34±8.21) ng/L], and the 6-keto-PGF1α level in DM plus fracture group was even lower (F=238.776, P=0.000). The levels of GMP-140, TXB2, FIB and DD in DM plus fracture group were (21.86±2.57) μg/L, (139.46±16.80) ng/L, (5.19±0. 89) g/L and (1.13±0. 27) mg/L, the corresponding four values in diabetic group and healthy control group were as follows: [(17.92±2. 50) μg/L and (13.85± 1.20)μg/L for GMP-1403, [(126.07±7.64) ng/L and (76.94±10.60) ng/L for TXB2], [(4.52± 0.80) g/L and (3.26±0.84) g/L for FIB] and [(0.73±0.27)mg/L and (0.29±0.15) mg/L for D-D], all measured values were significantly higher in the DM plus fracture, and DM groups than in healthy control group, and even higher in DM plus fracture group than in DM group (F= 191.407, 463.307, 90.705, 202.685, all P=0.000). Conclusions Fracture could enhance the coagulation activity and the high thrombotic state in type 2 diabetic patients, which may lead to thrombotic diseases, and need to be intervened early.
